Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512597 · ClinicalTrials.gov registry record · NA
Behavioral Therapy for Crohn's Disease
A NA study of Crohn's Disease, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 2
- Study locations
NCT06512597 is a NA study of Crohn's Disease that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 170 participants, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06512597, a NA study of Crohn's Disease, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 2
- Study locations
Study Summary
People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30% of people living with CD and 60% of inflammatory bowel disease (IBD) patients continue to report chronic pain, stress, sleeplessness, and fatigue, even when they are "objectively" in remission. Psychological stress has been endorsed by 70% of patients with IBD as a key trigger for disease activity which is not surprising given the significance of the gut-brain-microbiome axis, the close communication between the enteric and autonomic nervous systems, and the role of the hypothalamic-pituitary axis and its neuroendocrine and immune functions in the expression of GI symptoms. Interestingly, up to 85% of patients with CD also endorse the positive impact of effective coping skills on disease course. The PI's prior work has suggested that early provision of effective coping strategies, offered at the time of diagnosis or more precisely, immediately prior to biologic medication initiation, could potentially result in faster healing and improved well-being, likely through the combination of 1) physiological mitigation of the stress response and optimization of the gut-brain-microbiome axis; and 2) promotion of effective coping and disease self-management behaviors that promote psychological flourishing despite disease. Unfortunately, to date, early effective psychosocial care has been limited by concerns over reimbursement for psychological services, access to qualified IBD mental health professionals, and the lack of a standardized methodology focused on the brain-gut stress response and how to assess, monitor, communicate and maintain tight control over both physical and emotional well-being. CATHARSIS is a rigorous, placebo-controlled, randomized controlled trial of coping strategies plus medication for 17
Conditions Studied
Interventions
- BEHAVIORAL Primary Intervention for Combination Therapy - IBD Coping Strategies Program
- BEHAVIORAL Time and Attention Control - IBD Support Program
Study Locations (2)
New York
- Icahn School of Medicine at Mount Sinai - New York
- New York Gastroenterology Associates - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2028-07-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512597
The ClinicalTrials.gov registry entry for NCT06512597 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (93% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Primary Intervention for Combination Therapy - IBD Coping Strategies Program is the first listed.
NCT06512597 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06512597 about?
NCT06512597 is a clinical study titled "Behavioral Therapy for Crohn's Disease". People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30% of people living with CD and 60...
What is the current status of trial NCT06512597?
This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2024-11-01. Estimated completion is 2028-07-30.
What conditions does trial NCT06512597 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT06512597?
The interventions under investigation include: Primary Intervention for Combination Therapy - IBD Coping Strategies Program (BEHAVIORAL), Time and Attention Control - IBD Support Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06512597?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512597 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
RECRUITING · NA
-
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
RECRUITING · NA
-
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
ACTIVE NOT RECRUITING · NA
-
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease
COMPLETED · NA
-
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
COMPLETED · NA
-
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.